Capricor Therapeutics, Inc. (4LN2.F)
| Previous close | 4.81 |
| Open | 5.21 |
| Bid | 5.65 x N/A |
| Ask | 5.80 x N/A |
| Day's range | 5.14 - 5.21 |
| 52-week range | 2.50 - 7.13 |
| Volume | |
| Avg. volume | 97 |
| Market cap | 181.488M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.76 |
| Earnings date | 05 Aug 2024 - 09 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.50 |
- GuruFocus.com
Capricor Therapeutics Inc (CAPR) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Unveiling key financial outcomes and strategic milestones, Capricor Therapeutics sets a robust path for 2024.
ZacksCapricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates
Capricor (CAPR) delivered earnings and revenue surprises of -181.82% and 50.93%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireCapricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
–Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 2024– –Positive Type-B CMC FDA Meeting held in Q1; Company Aligned with FDA on Demonstration of Non-Clinical Comparability, A Major Milestone on Path to CMC Clearance for BLA– –Received First Milestone Payment of $10 Million under U.S. Distribution and Commercialization Agreement with Nippon Shinyaku in Q1– –Recent FDA Feedback Supports Requests for a Pre-BLA Meetin
